<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Epidemiology and Infectious Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Epidemiology and Infectious Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиология и инфекционные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">3034-2007</issn><issn publication-format="electronic">3034-2015</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">627198</article-id><article-id pub-id-type="doi">10.17816/EID627198</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Predicting COVID-19 outcomes in patients at advanced stages of HIV infection: a model-based approach</article-title><trans-title-group xml:lang="ru"><trans-title>Прогнозирование исходов COVID-19 у пациентов с продвинутыми стадиями ВИЧ-инфекции: подход, основанный на создании предсказательной модели</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3766-1868</contrib-id><contrib-id contrib-id-type="researcherid">HDM-3718-2022</contrib-id><contrib-id contrib-id-type="spin">6583-0476</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsygankova</surname><given-names>Anna E.</given-names></name><name xml:lang="ru"><surname>Цыганкова</surname><given-names>Анна Эдуардовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><bio xml:lang="ru"><p>ассистент кафедры инфекционных болезней</p></bio><email>anna.tsygankova.inf@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6303-9293</contrib-id><contrib-id contrib-id-type="spin">2336-4545</contrib-id><name-alternatives><name xml:lang="en"><surname>Chulanov</surname><given-names>Vladimir P.</given-names></name><name xml:lang="ru"><surname>Чуланов</surname><given-names>Владимир Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>доктор медицинских, профессор</p></bio><email>vladimir.chulanov@rcvh.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4549-7172</contrib-id><contrib-id contrib-id-type="scopus">141741</contrib-id><contrib-id contrib-id-type="spin">4742-1459</contrib-id><name-alternatives><name xml:lang="en"><surname>Gerasimov</surname><given-names>Andrey N.</given-names></name><name xml:lang="ru"><surname>Герасимов</surname><given-names>Андрей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Phys.-Math.), Associate Professor</p></bio><bio xml:lang="ru"><p>доктор ф.-м. наук, доцент</p></bio><email>andr-gerasim@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4581-4510</contrib-id><contrib-id contrib-id-type="spin">3342-4681</contrib-id><name-alternatives><name xml:lang="en"><surname>Volchkova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Волчкова</surname><given-names>Елена Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор</p></bio><email>antononina@rambler.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4827-1673</contrib-id><name-alternatives><name xml:lang="en"><surname>Privalenko</surname><given-names>Anton A.</given-names></name><name xml:lang="ru"><surname>Приваленко</surname><given-names>Антон Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>medical statistician</p></bio><bio xml:lang="ru"><p>медицинский статистик</p></bio><email>antochka001@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6065-2922</contrib-id><contrib-id contrib-id-type="spin">9446-5319</contrib-id><name-alternatives><name xml:lang="en"><surname>Bakhtina</surname><given-names>Viktoriya A.</given-names></name><name xml:lang="ru"><surname>Бахтина</surname><given-names>Виктория Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук </p></bio><email>dom-167@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khabudaev</surname><given-names>Vladimir A.</given-names></name><name xml:lang="ru"><surname>Хабудаев</surname><given-names>Владимир Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук </p></bio><email>ioikb@ioikb.ru</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5518-9301</contrib-id><contrib-id contrib-id-type="spin">9039-7431</contrib-id><name-alternatives><name xml:lang="en"><surname>Baimukhambetova</surname><given-names>Dina V.</given-names></name><name xml:lang="ru"><surname>Баймухамбетова</surname><given-names>Дина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>6th year student</p></bio><bio xml:lang="ru"><p>студентка 6 курса Института клинической медицины им. Н.В. Склифосовского</p></bio><email>dbaimukhambietova@bk.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Central Research Institute of Epidemiology</institution></aff><aff><institution xml:lang="ru">Центральный научно-исследовательский институт эпидемиологии</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Specialized Clinical Infectious Hospital</institution></aff><aff><institution xml:lang="ru">Специализированная клиническая инфекционная больница</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Irkutsk Regional Clinical Hospital</institution></aff><aff><institution xml:lang="ru">Иркутская областная клиническая больница</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-03-11" publication-format="electronic"><day>11</day><month>03</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-03-01" publication-format="electronic"><day>01</day><month>03</month><year>2024</year></pub-date><volume>29</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>5</fpage><lpage>17</lpage><history><date date-type="received" iso-8601-date="2024-02-20"><day>20</day><month>02</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-03-11"><day>11</day><month>03</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-вектор</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-03-01"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjeid.com/1560-9529/article/view/627198">https://rjeid.com/1560-9529/article/view/627198</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND</bold>: Today, clinicians and their decisions extensively rely on specific treatment algorithms. These algorithms include prognostic models to identify high risk patients requiring hospital admission and clinical monitoring. This study suggests a prognostic model for forecasting COVID-19 outcomes in patients with advanced HIV infection, considering the high risk of unfavorable outcomes and the need for a specialized approach.</p> <p><bold>AIM:</bold> To develop a prognostic model that combines predictors of unfavorable COVID-19 outcomes in patients with advanced HIV infection.</p> <p><bold>MATERIALS AND METHODS:</bold> The study was based on 500 medical records of patients with advanced HIV infection admitted for confirmed COVID-19 between March 1, 2020, and December 31, 2022, and inpatient treatment at the Infectious Diseases Hospital in Moscow.</p> <p><bold>RESULTS:</bold> All 500 patients were evaluated for 167 predictive markers for unfavorable COVID-19 outcomes, outlining 50 indicators that significantly varied across the subgroups of patients with both advanced HIV infection and COVID-19 depending on the presence of favorable or poor outcomes. Oxygen therapy was the most significant factor showing a strong correlation with poor outcomes in patients with advanced HIV infection and COVID-19. Subsequently, predictors were selected stepwise to enhance the predictive accuracy of the resulting model by adding more factors.</p> <p>The resulting model included seven factors: oxygen therapy requirements, CD4+ count under 50 cells/μL; manifested CMV infection with lung damage; elevated levels of lactate dehydrogenase, urea, and fibrinogen; and the presence of unspecified encephalitis. Using the available data in the calculations, a prognostic scenario and a receiver operating characteristic (ROC) curve were created to assess the practical significance of the proposed prognostic model. The area under the ROC curve was 90.9%, confirming the prediction accuracy and overall practical significance of the model.</p> <p><bold>CONCLUSIONS:</bold> The proposed prognostic model enables the assessment of potential outcomes and planning of adequate therapies in patients with HIV and COVID-19 co-infection admitted to hospitals at advanced stages of the disease.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> В настоящее время повсеместно внедряются системы поддержки принятия врачебных решений. Одним из таких инструментов может быть прогностическая модель, способная выделять пациентов высокого риска, которым необходима госпитализация и клинический мониторинг. В этой статье предлагается прогностическая модель исходов COVID-19 у пациентов с ВИЧ-инфекцией на стадии вторичных заболеваний, поскольку эти пациенты являются группой риска неблагоприятного исхода и требуют особого подхода.</p> <p><bold>Цель исследования — </bold>создание прогностической модели предикторов неблагоприятных исходов COVID-19 у пациентов с ВИЧ-инфекцией на стадии вторичных заболеваний.</p> <p><bold>Материалы и методы.</bold> Проведён анализ 500 историй болезней госпитализированных пациентов с ВИЧ-инфекцией на стадии вторичных заболеваний и подтверждённым COVID-19, проходивших стационарное лечение в инфекционной клинической больнице № 2 г. Москвы с 1 марта 2020 года по 31 декабря 2022 года.</p> <p><bold>Результаты.</bold> В качестве возможных предикторов неблагоприятного исхода COVID-19 у пациентов с COVID-19 были оценены 167 показателей укаждого из 500 пациентов. Затем были выделены 50 факторов, которые достоверно различались в группах пациентов с COVID-19 и ВИЧ-инфекцией на стадии вторичных заболеваний с благоприятным и летальным исходом. Наиболее значимым фактором, имеющим корреляционную силу с летальным исходом у пациентов с COVID-19 и ВИЧ-инфекцией на стадии вторичных заболеваний, стала необходимость в кислородной поддержке. Отбор последующих предикторов производился пошаговым методом, чтобы при добавлении факторов возрастала предсказательная точность полученной модели.</p> <p>В итоговую модель вошли 7 факторов: необходимость в осуществлении кислородной поддержки, число CD4+ лимфоцитов менее 50 кл/мкл, манифестная цитомегаловирусная инфекция с поражением лёгких, показатель уровня лактатдегидрогеназы выше нормы, энцефалит неуточнённой этиологии, уровень мочевины, показатель уровня фибриногена выше нормы. Для оценки практической значимости полученной прогностической модели был рассчитан прогноз для имеющихся данных и построена ROC-кривая. Площадь под кривой составила 90,9%, что подтверждает точность прогнозирования, имеющую практическую значимость.</p> <p><bold>Заключение.</bold> Созданная прогностическая модель позволяет оценить возможный исход инфекционного процесса у пациентов с COVID-19 и ВИЧ-инфекцией на поздних стадиях на момент поступления в стационар и на основании полученного результата спланировать адекватные терапевтические мероприятия.</p></trans-abstract><kwd-group xml:lang="en"><kwd>HIV</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ВИЧ-инфекция</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Royal College of Physicians. National Early Warning Score (NEWS): Standardising the assessment of acuteillness severity in the NHS. London: RCP; 2012.</mixed-citation><mixed-citation xml:lang="ru">Royal College of Physicians. National Early Warning Score (NEWS): Standardising the assessment of acuteillness severity in the NHS. London : RCP, 2012.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Zheng Z, Peng F, Xu B, et al. Risk factors of critical &amp; mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. doi: 10.1016/j.jinf.2020.04.021</mixed-citation><mixed-citation xml:lang="ru">Zheng Z., Peng F., Xu B., et al. Risk factors of critical &amp; mortal COVID-19 cases: A systematic literature review and meta-analysis // J Infect. 2020. Vol. 81, N 2. P. e16–e25. doi: 10.1016/j.jinf.2020.04.021</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med. 2020;9(2):428–436. doi: 10.21037/apm.2020.03.26</mixed-citation><mixed-citation xml:lang="ru">Zhou Y., Zhang Z., Tian J., Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus // Ann Palliat Med. 2020. Vol. 9, N 2. P. 428–436. doi: 10.21037/apm.2020.03.26</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versii 3–18. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. [Internet]. (In Russ). Available at: https://minzdrav.gov.ru/ministry/med_covid19.</mixed-citation><mixed-citation xml:lang="ru">Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версии 3–18 // Министерство здравоохранения Российской Федерации [интернет]. Режим доступа: https://minzdrav.gov.ru/ministry/med_covid19.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328</mixed-citation><mixed-citation xml:lang="ru">Wynants L., Van Calster B., Collins G.S., et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal // BMJ. 2020. Vol. 369. P. m1328. doi: 10.1136/bmj.m1328</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Prikaz Ministerstva zdravookhraneniya Rossiiskoi Federatsii ot 9 noyabrya 2012 g. № 758n “Ob utverzhdenii standarta spetsializirovannoi meditsinskoi pomoshchi pri bolezni, vyzvannoi virusom immunodefitsita cheloveka (VICh-infektsii)” [Internet]. (In Russ). Available at: https://minzdrav.gov.ru/documents/8837-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-9-noyabrya-2012-g-758n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-bolezni-vyzvannoy-virusom-immunodefitsita-cheloveka-vich-infektsii.</mixed-citation><mixed-citation xml:lang="ru">Приказ Министерства здравоохранения Российской Федерации от 9 ноября 2012 г. № 758н «Об утверждении стандарта специализированной медицинской помощи при болезни, вызванной вирусом иммунодефицита человека (ВИЧ-инфекции)» [интернет]. Режим доступа: https://minzdrav.gov.ru/documents/8837-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-9-noyabrya-2012-g-758n-ob-utverzhdenii-standarta-spetsializirovannoy-meditsinskoy-pomoschi-pri-bolezni-vyzvannoy-virusom-immunodefitsita-cheloveka-vich-infektsii.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Gerasimov AN, Morozova NI. Parametric and Nonparametric Methods in Medical Statistics. Epidemiology and Vaccinal Prevention. 2015;14(5):6–12. (In Russ). doi: 10.31631/2073-3046-2015-14-5-6-12</mixed-citation><mixed-citation xml:lang="ru">Герасимов А.Н., Морозова Н.И. Параметрические и непараметрические методы в медицинской статистике // Эпидемиология и Вакцинопрофилактика. 2015. Т. 14, № 5. С. 6–12. doi: 10.31631/2073-3046-2015-14-5-6-12</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Chen R, Liang W, Jiang M, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest. 2020;158(1):97–105. doi: 10.1016/j.chest.2020.04.010</mixed-citation><mixed-citation xml:lang="ru">Chen R., Liang W., Jiang M., et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China // Chest. 2020. Vol. 158, N 1. P. 97–105. doi: 10.1016/j.chest.2020.04.010</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Nagibina MV, Smirnov NA, Bessarab TP, et al. Analysis of the course and outcomes of COVID-19 in HIV infected patients according to the infectious diseases’ hospital of Moscow. Clinical Medicine (Russian Journal). 2023;101(2-3):93–100. (In Russ). doi: 10.30629/0023-2149-2023-101-2-3-93-100</mixed-citation><mixed-citation xml:lang="ru">Нагибина М.В., Смирнов Н.А., Бессараб Т.П., и др. Анализ течения и исходов COVID-19 у ВИЧ-инфицированных пациентов по данным инфекционного стационара города Москвы // Клиническая медицина. 2023. Т. 101, № 2-3. С. 93–100. doi: 10.30629/0023-2149-2023-101-2-3-93-100</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021;73(7):e1964–e1972. doi: 10.1093/cid/ciaa1339</mixed-citation><mixed-citation xml:lang="ru">Dandachi D., Geiger G., Montgomery M.W., et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019 // Clin Infect Dis. 2021. Vol. 73, N 7. P. e1964–e1972. doi: 10.1093/cid/ciaa1339</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Yendewa GA, Perez JA, Schlick K, Tribout H, McComsey GA. Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX). Open Forum Infect Dis. 2021;8(7):ofab272. doi: 10.1093/ofid/ofab272</mixed-citation><mixed-citation xml:lang="ru">Yendewa G.A., Perez J.A., Schlick K., Tribout H., McComsey G.A. Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX) // Open Forum Infect Dis. 2021. Vol. 8, N 7. P. ofab272. doi: 10.1093/ofid/ofab272</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022;19(1):3. doi: 10.1186/s12981-021-00427-y</mixed-citation><mixed-citation xml:lang="ru">Danwang C., Noubiap J.J., Robert A., Yombi J.C. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis // AIDS Res Ther. 2022. Vol. 19, N 1. P. 3. doi: 10.1186/s12981-021-00427-y</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin Infect Dis. 2021;73(7): e2095–e2106. doi: 10.1093/cid/ciaa1605</mixed-citation><mixed-citation xml:lang="ru">Geretti A.M., Stockdale A.J., Kelly S.H., et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study // Clin Infect Dis. 2021. Vol. 73, N 7. P. e2095–e2106. doi: 10.1093/cid/ciaa1605</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kassanjee R, Davies MA, Ngwenya O, et al. COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa. J Int AIDS Soc. 2023;26(6):e26104. doi: 10.1002/jia2.26104</mixed-citation><mixed-citation xml:lang="ru">Kassanjee R., Davies M.A., Ngwenya O., et al. COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa // J Int AIDS Soc. 2023. Vol. 26, N 6. P. e26104. doi: 10.1002/jia2.26104</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Sun J, Jiang R, Shao Y, et al. Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19. Chin Med J (Engl). 2023;136(22):2753–2755. doi: 10.1097/CM9.0000000000002902</mixed-citation><mixed-citation xml:lang="ru">Sun J., Jiang R., Shao Y., et al. Antiretroviral therapy-naïve people living with HIV tend to have more severe symptoms of COVID-19 // Chin Med J (Engl). 2023. Vol. 136, N 22. P. 2753–2755. doi: 10.1097/CM9.0000000000002902</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Marmorino F, Salvatore L, Barbara C, et al. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. Br J Cancer. 2017;116(3):318–323. doi: 10.1038/bjc.2016.413</mixed-citation><mixed-citation xml:lang="ru">Marmorino F., Salvatore L., Barbara C., et al. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer // Br J Cancer. 2017. Vol. 116, N 3. P. 318–323. doi: 10.1038/bjc.2016.413</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Lu J, Wei Z, Jiang H, et al. Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study. J Surg Res. 2018;228:314–321. doi: 10.1016/j.jss.2018.03.035</mixed-citation><mixed-citation xml:lang="ru">Lu J., Wei Z., Jiang H., et al. Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study // J Surg Res. Vol. 228. P. 314–321. doi: 10.1016/j.jss.2018.03.035</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Gulhar R, Ashraf MA, Jialal I. Physiology, Acute Phase Reactants. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: http://www.ncbi.nlm.nih.gov/books/NBK519570.</mixed-citation><mixed-citation xml:lang="ru">Gulhar R., Ashraf M.A., Jialal I. Physiology, Acute Phase Reactants. In: StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing, 2024. Available at: http://www.ncbi.nlm.nih.gov/books/NBK519570.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5): 377–382. doi: 10.1136/thorax.58.5.377</mixed-citation><mixed-citation xml:lang="ru">Lim W.S, van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study // Thorax. 2003. Vol. 58, N 5. P. 377–382. doi: 10.1136/thorax.58.5.377</mixed-citation></citation-alternatives></ref></ref-list></back></article>
